1. A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting.
- Author
-
Hicks SM, Pohl K, Neeman T, McNamara HA, Parsons KM, He JS, Ali SA, Nazir S, Rowntree LC, Nguyen THO, Kedzierska K, Doolan DL, Vinuesa CG, Cook MC, Coatsworth N, Myles PS, Kurth F, Sander LE, Mann GJ, Gruen RL, George AJ, Gardiner EE, and Cockburn IA
- Subjects
- Antigens, Viral immunology, Australia, COVID-19 immunology, Coronavirus Nucleocapsid Proteins immunology, Humans, Immunoglobulin G analysis, Phosphoproteins immunology, Sensitivity and Specificity, Spike Glycoprotein, Coronavirus immunology, Antibodies, Viral analysis, COVID-19 diagnosis, Enzyme-Linked Immunosorbent Assay, Seroepidemiologic Studies
- Abstract
Estimates of seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies have been hampered by inadequate assay sensitivity and specificity. Using an enzyme-linked immunosorbent assay-based approach that combines data about immunoglobulin G responses to both the nucleocapsid and spike receptor binding domain antigens, we show that excellent sensitivity and specificity can be achieved. We used this assay to assess the frequency of virus-specific antibodies in a cohort of elective surgery patients in Australia and estimated seroprevalence in Australia to be 0.28% (95% Confidence Interval, 0-1.15%). These data confirm the low level of transmission of SARS-CoV-2 in Australia before July 2020 and validate the specificity of our assay., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF